Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 6/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30836614 | 0.89 | LIPE (0.50) | LIPENPC1MEN1AHRKMT2A | |
| SCHEMBL20293126 | 0.89 | LIPE (0.50) | LIPENPC1SMN1; SMN2MEN1AHR | |
| SCHEMBL30836715 | 0.89 | LIPE (0.50) | LIPENPC1SMN1; SMN2MEN1AHR | |
| SCHEMBL20293697 | 0.89 | LIPE (0.50) | LIPENPC1MEN1AHRKMT2A | |
| SCHEMBL21623038 | 0.76 | LIPE (0.45) | LIPEMEN1AHRKMT2A | |
| SCHEMBL31108221 | 0.75 | LIPE (0.41) | LIPESMN1; SMN2BACE1BACE2 | |
| SCHEMBL26922878 | 0.73 | LIPE (0.43) | LIPENPC1MEN1KMT2ACXCR2 | |
| SCHEMBL20323960 | 0.73 | MEN1 (0.37) | LIPENPC1SMN1; SMN2MEN1AHR | |
| SCHEMBL31108271 | 0.73 | LIPE (0.52) | LIPEMEN1AHRKMT2ACXCR2 | |
| SCHEMBL28793298 | 0.73 | LIPE (0.52) | LIPEMEN1AHRKMT2ACXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-3558963-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3558963-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119286-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LIPE 3447/4885NPC1 945/4885SMN1; SMN2 4177/4885 |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LIPE 3447/4885NPC1 945/4885SMN1; SMN2 4177/4885 |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | LIPE 3447/4885NPC1 945/4885SMN1; SMN2 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.